Cocrystal Pharma (NASDAQ:COCP) Releases Earnings Results, Misses Expectations By $0.02 EPS

Cocrystal Pharma (NASDAQ:COCP) posted its quarterly earnings data on Friday. The company reported ($0.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.02), FiscalAI reports.

Cocrystal Pharma Trading Down 4.8%

Shares of COCP stock traded down $0.06 on Friday, reaching $1.20. 101,244 shares of the stock were exchanged, compared to its average volume of 150,678. Cocrystal Pharma has a twelve month low of $0.86 and a twelve month high of $2.67. The company has a market capitalization of $16.55 million, a price-to-earnings ratio of -1.52 and a beta of 1.50. The business’s 50 day moving average price is $1.27 and its 200 day moving average price is $1.11.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Cocrystal Pharma stock. DRW Securities LLC bought a new stake in Cocrystal Pharma, Inc. (NASDAQ:COCP) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 33,593 shares of the company’s stock, valued at approximately $33,000. DRW Securities LLC owned approximately 0.24% of Cocrystal Pharma at the end of the most recent quarter. Institutional investors and hedge funds own 6.72% of the company’s stock.

About Cocrystal Pharma

Cocrystal Pharma, Inc (NASDAQ:COCP) is a clinical-stage biotechnology company focused on the discovery and development of novel antiviral therapeutics. Utilizing an integrated structure-guided drug design platform, the company combines x-ray crystallography, computational chemistry and medicinal chemistry to identify and optimize small molecule inhibitors targeting key viral enzymes. This approach is intended to accelerate the progression of lead candidates from discovery through preclinical development.

The company’s pipeline includes multiple preclinical programs aimed at treating respiratory and systemic viral infections.